Movement Alert｜METIS TECHBIO-P Intraday Rise 5.81% in Regular Trading, Lilly LNP collaboration continues to drive platform re-rating expectations

Market Focus10-21

On October 21, METIS TECHBIO-P rose 5.81% in Regular Trading, trading at HK$12.04, with turnover of HK$14.96 million.

The move followed continued market digestion of the company’s newly announced strategic collaboration with Eli Lilly on next-generation tissue-specific LNP delivery technology.

Under the disclosed terms, METIS TECHBIO-P will receive an upfront payment in the low double-digit millions of U.S. dollars and may earn up to about $1.1 billion in development, regulatory, and commercial milestones, plus single-digit tiered royalties. The partnership will use its AI-driven AiLNP platform to discover and optimize novel lipid nanoparticle architectures aimed at improving tissue-specific delivery, reinforcing investor focus on the commercialization value of its NanoForge platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment